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The importance of posttranslational modifications for sirtuin 
activities is discussed in the article “Regulation of sirtuin function 
by posttranslational modifications.” Here the authors review the 
posttranslational regulation mechanisms of mammalian sirtuins 
and discuss their relevance regarding the physiological processes. 
Based on available data they suggest that the N- and C-termini 
are the targets of posttranslational modifications, which in turn 
determines differential interaction with catalytic core domain. The 
authors emphasize the key regulatory roles of the N- and C-termini 
in controlling different signaling pathways.
The article “Role and therapeutic potential of the pro-lon-
gevity factor FOXO and its regulators in neurodegenerative dis-
ease” is focused on downstream sirtuin targets, critical for aging, 
and age-related neurodegeneration. The author discusses FOXO 
network of transcription factors, which is most notable for its 
association with longevity and modulation by upstream regula-
tors such as sirtuins. He emphasizes that the FOXO network is a 
complex stress response system and thus development of disease-
modifying strategies requires careful examination. C. Neri argues 
that although the FOXO network contains druggable genes such 
as sirtuins, whether they should be activated or inhibited and 
whether protection against the early or late phases of neuronal 
cell decline might require opposite therapeutic strategies remains 
unclear.
Next, the complexity of therapeutic targeting of sirtuins is dis-
cussed in the article “SIRT2 as a therapeutic target for age-related 
disorders.” The authors discuss the second member of sirtuin fam-
ily, SIRT2, its physiological role(s) in various cellular environ-
ments and tissue-specific functions. This article summarizes the 
main scientific advances on SIRT2 protein biology and explores 
its potential as a therapeutic target for treatment of age-related 
disorders.
In the article “Inhibition of sirtuin 2 with sulfobenzoic acid 
derivative AK1 is non-toxic and potentially neuroprotective in 
a mouse model of frontotemporal dementia” the authors pro-
vide experimental evidence on the efficacy of SIRT2 inhibitor 
in mouse brain. The rTg4510 mouse model, which expresses 
a mutant form of the tau protein associated with FTD with 
Parkinsonism, undergoes dramatic hippocampal and cortical 
neuronal loss. In present study, the SIRT2 inhibitor was directly 
delivered to the hippocampus with an osmotic minipump. The 
treatment was found to be safe in wild-type and transgenic mice 
and, furthermore, it provided neuroprotection in the rTg4510 
hippocampal circuitry. This study provides proof-of-concept for 
therapeutic benefits of SIRT2 inhibitors in both tau-associated 
FTD and Alzheimer’s disease.
The sirtuin family of NAD+-dependent enzymes has received much 
of attention in recent years due to their diverse physiological func-
tions in metabolism, aging, and age-related human diseases. The 
mammalian sirtuins (SIRT1-7) act as NAD+-dependent protein 
deacetylases and weak mono-ADP-ribosyl transferases on a variety 
of targets, including histones, transcription factors, and apoptotic 
modulators. The sirtuins appear to be the key sensors for available 
energy stores, which function as molecular switch between protein 
acetylation and metabolism. Furthermore, it has been shown in a 
broad range of experimental disease models, from yeast to mouse 
models, that modulation of sirtuin activities, particularly that of the 
most studied SIRT1 protein, suppresses or ameliorates pathologi-
cal states, and thus sirtuins constitute attractive novel therapeutic 
targets for many age-related disorders, for most metabolic disorders 
such as diabetes and obesity.
The major goal of this Special Issue is to discuss and evaluate 
the current knowledge on sirtuin biology for a rational approach 
toward the development sirtuin-based therapeutics.
In the article “Sirtuins as regulators of the yeast metabolic net-
work” the authors discuss a network complexity of yeast SIRT1 
homolog. The archetypal sirtuin, yeast silent information regulator2 
(SIR2), is an NAD+ dependent protein deacetylase that interacts 
with metabolic enzymes glyceraldehyde-3-phosphate dehydro-
genase and alcohol dehydrogenase, as well as enzymes involved 
in NAD(H) synthesis, that provide or deprive NAD+ in its close 
proximity. This influences sirtuin activity, and facilitates a dynamic 
response of the metabolic network to changes in metabolism with 
effects on physiology and aging. The molecular network down-
stream Sir2, however, is complex, and tertiary interactions of Sir2, 
relevant to metabolic regulation, involve half of the yeast proteome.
The SIRT1 network is further discussed in the manuscript 
“Interactomic and pharmacological insights on human SIRT1.” 
The article presents studies on human SIRT1, which illuminate 
functional relationships of gene–protein interactions, controlling 
major metabolic pathways. This article also shows the mechanism 
of binding of small molecule activators and discusses critical struc-
tural determinants and physico-chemical features important for 
rational design of SIRT1 effectors.
Rational drug design is also the topic of the article “Structures, 
substrates, and regulators of mammalian Sirtuins – opportunities 
and challenges for drug development.” The authors recapitulate 
advances in structural and mechanistic studies on substrate recog-
nition and deacetylation by sirtuins, which provides a basis for the 
identification and characterization of small molecule sirtuin activa-
tors and inhibitors as well as evaluation the molecular mechanisms 
regulating their activities.
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An apparent link between sirtuin modalities and cancer has 
emerged and is discussed in the two articles, “Sirtuins and disease: 
the road ahead” and “Sirtuins, Metabolism, and Cancer.” In the first 
article the authors discuss experimental evidences suggesting a criti-
cal role for SIRT1 in tumor initiation and progression as well as drug 
resistance by blocking senescence and apoptosis, and by promoting 
cell growth and angiogenesis. The present article highlights sirtuin 
mechanism(s) of action and deregulation in cancer, and focuses on the 
therapeutic potential of sirtuin modulators both in cancer prevention 
and treatment. In the second paper authors specifically review recent 
progress on the role of sirtuins in DNA repair and energy metabolism, 
and further address the sirtuin role(s) in the biology of cancer.
Overall, the present special issue “Sirtuins in Biology and 
Disease” provides an overview and insight on therapeutic potentials 
of sirtuin-based therapeutics and discusses the evident complexity 
of drug-targeting these modalities for human indications.
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